Skip to main content
. Author manuscript; available in PMC: 2015 Mar 9.
Published in final edited form as: J Immunother. 2015 Jan;38(1):24–36. doi: 10.1097/CJI.0000000000000059

Figure 2. Allo-NK cells proliferated further after infusion and circulating NK retained lytic activity against myeloma cells.

Figure 2

A. The absolute number of NK cells per μL PB increased significantly post-infusion in subject 5. B. Chimerism studies confirmed that circulating PBMC in subject 5 were of donor origin. C. NK cells isolated from day 5 and day 7 post-infusion PB samples avidly killed subject 5 myeloma cells and K562 cells (51Cr release assay). D. Significantly higher NK cell levels were observed in the PB and BM of subject 8 who received NK produced in high IL2 (500 U/mL). E. The vast majority of post-infusion cells were of donor origin. F. Circulating NK cells obtained 14 days after infusion from the PB of subject 8 killed OPM2 myeloma and K562 cells (subject 8 myeloma was not available).